Overview

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection

Status:
Not yet recruiting
Trial end date:
2022-09-20
Target enrollment:
Participant gender:
Summary
Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection (FRSW107) Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in Severe Hemophilia A.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Gensciences lnc.